DAPTA, also known as Adaptavir, is primarily used in research and therapeutic applications due to its immunomodulatory properties. It functions as a chemokine receptor antagonist, specifically targeting CCR5, which plays a role in inflammatory processes and viral infections. This makes it a potential candidate for treating conditions like HIV, as CCR5 is a co-receptor for viral entry into cells. Additionally, its anti-inflammatory effects are being explored for managing autoimmune diseases and neuroinflammatory disorders. Research is ongoing to evaluate its efficacy in reducing inflammation and modulating immune responses in various clinical settings.